

Development of a Novel HILIC HPLC/MS/MS Bioanalytical Method for the Quantitative Analysis of Carboplatin from the Plasma of Mouse

Chad Christianson and Shane Needham


Alturas Analytics, Inc., Moscow, ID 83843

Overview

- **Purpose** - Develop an HPLC/MS/MS method to determine concentrations of Carboplatin, an organo-metallic drug, in plasma, when typical HPLC/MS/MS methods are unsuccessful
- **Methods** – 96 well-plate extraction and HPLC/ESI/MS/MS
- **Results** – Range from 25-10,000 nM with accuracies and precision better than 25% using Hydrophilic Interaction Liquid Chromatography (HILIC)

Introduction

Carboplatin is a drug that is used as a chemotherapy treatment for cancer. Measurement of carboplatin by HPLC/UV methods is insensitive due to the lack of significant UV absorption. Although derivitization of carboplatin has been used, these methods only produced limits of quantitation near 0.13 μ M and required run times of >25 minutes per sample. Other HPLC/MS methods required extensive clean-up of the biological samples. In addition, the HPLC/MS methods suffered from assay interferences due to lack of retention of the polar carboplatin on the reversed phase column. Here we report on the development of a precipitation method with a polar HPLC column (HILIC) for the sensitive HPLC/MS/MS quantitative analysis of carboplatin from plasma.



Methods

Extraction

- Simple 3:1 acetonitrile precipitation of Carboplatin from mouse plasma in 96 well plates

HPLC USING HILIC

- Gradient from 18% to 32% aqueous in 4 minutes. Hold for 1.0 minute
- Flow rate = 0.4 mL/minute
- 1% formic acid Acetonitrile and Water
- Polyhydroxy Ethyl A 2.1x100 mm (PolyLC, Columbia, MD)
- Direct 30 μ L injection of supernatant

Mass Spectrometry

- Sciex API3000 operating in MRM mode
- Turboionspray (400 °C)
- Positive ion mode
- MRM transitions for Carboplatin–
• m/z 372 \rightarrow 294

Other HPLC Results

- Conventional C8 or C18 columns were not successful in retaining Carboplatin
- Polar embedded reversed-phase columns even with ion-pair reagents were not successful in retaining Carboplatin
- Bare silica was not successful in retaining Carboplatin – Thus not an ion-exchange mechanism
- pH of the mobile phase had an insignificant influence on the retention of Carboplatin on Polyhydroxy Ethyl A – Thus not an ion-exchange mechanism
- The percent organic had the most significant affect on the retention of Carboplatin on Polyhydroxy Ethyl A


All the above results lead to the conclusion that the dominant chromatographic interaction is HILIC

Table 1. Standard Curve and QC Results for the HPLC/MS/MS Analysis of Carboplatin from Mouse Plasma


$r^2=0.997$

| Standard Curve Level (nM) | Calculated Concentration (nM) | % Accuracy |
|---------------------------|-------------------------------|------------|
| 25 | 27.4 | 110 |
| 50 | 61.8 | 124 |
| 100 | 112 | 112 |
| 500 | 493 | 98.6 |
| 1000 | 943 | 94.3 |
| 2500 | 2330 | 93.2 |
| 5000 | 4350 | 87.0 |
| 10000 | 7850 | 78.5 |
| QC-2500 | 1950 | 78.0 |
| QC-2500 | 1980 | 79.2 |

HPLC/MS/MS Chromatogram from the Analysis of a Standard Fortified with Carboplatin at 5000 ng/mL and Extracted from Mouse Plasma



HPLC/MS/MS Chromatogram from the Analysis for Carboplatin from a Mouse Plasma Sample 75 Minutes Post-Dose



Conclusions

- Developed HPLC/MS/MS method to quantify the organo-metallic drug Carboplatin from mouse plasma
- Found that the HPLC chromatographic interaction was predominantly HILIC
- Method supports PK studies for Carboplatin
- Future work will investigate other types of HILIC stationary phases to obtain more narrow peaks, and thus improve detection limits
- Investigate use of labeled internal standard to improve accuracy